You are here

Home » Content

ANTI CANCEROUS EFFECT OF NANO-ENGINEERED ENCAPSULATING CHEMOTHERAPEUTIC DRUG ON HUMAN COLORECTAL HT-29 CELL LINE.

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
Colorectal cancer is fourth most prevalent cancer worldwide. In recent years, there have been important advances in the management of colorectal cancer. Several obstacles frequently encountered with anticancer compounds, such as toxicity of drugs to normal tissues, poor specificity and stability and a high incidence of drug-resistant tumor cells, are at least partially overcome by delivering them using solid lipid nanoparticles (SLN). Therefore, a need is felt to incorporate chemotherapeutic drugs into better drug delivery carriers such as SLN to minimize systemic side effects and toxicity. Measures of anti-carcinogenic potential of the nano-engineered formulations were investigated using cultured adenocarcinoma cells. Evaluation of anti-carcinogenic potential by Annexin-V-FITC/PI apoptosis assay following 48 h treatment with SLN and native drugs delineated significant differences, establishing better potential efficacy of nano-engineered drugs. Higher internalizing ability, better antitumor efficacy and lesser cytotoxicity of SLNs was attributed to increased accumulation of drugs in cancerous cells. The results of our study implied that these nano-carriers could possibly enhance antitumor effect in vivo with low systemic toxicity for the treatment of malignant cells.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon ijprbs_168.16.pdf
  • 5
250-260
  • English

REFERENCES

References: 

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun M J: Cancer statistics, CA Cancer J Clin. 2007; 57: 43.
2. Adiga S M, Kumari M K, Bairy K L, Mohan Babu A, Vadiraja B M and Vidyasagar M S: The effect of using combination chemotherapy in colorectal cancer in India: A single institute survey, Cancer Res Exp Oncol, 2010; 2: 001.
3. Hill M J, Morsan B C and Bussey H J: Aetiology of adenoma-carcinoma sequence in large bowel, Lancet. 1978; 1: 245.
4. Albet D S: Reducing the risk of colorectal cancer by intervening in the process of carcinogenesis: a status report, Cancer J. 2002; 8: 208.
5. Frei E III and Antman K H: Combination chemotherapy, dose, and schedule, in Cancer Medicine. 1997: 817.
6. Douillard J Y, Cunningham D and Roth A D: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet. 2000; 355: 1041.
7. Saltz L B, Cox J V and Blanke C: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer, N Engl J Med. 2000: 905.
8. Kulig J, Popiela T, Richter P and Klek S: Evaluation adjuvant chemotherapy irinotecan + 5 fluorouracil + leucovorin in advanced colorectal cancer, Acta Cher Belg. 2007; 107: 297.
9. Tournigand C, Andre T, Achille E, Lledo G, Flesh M and Merymignard D: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol. 2004; 22: 229.
10. Hwang J J, Eisenberg S G and Marshall J L: Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule, Oncology. 2003; 17: 37.
11. Douillard J Y: Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer, Oncology. 2000; 14: 51.
12. Magrath I T: Targeted approaches to cancer therapy, Int J Cancer. 1994; 56: 163.
Available Online At www.ijprbs.com
Research Article
Sourabh
Tiwari, IJPRBS, 2012; Volume 1(5): 250-260
ISSN: 2277-8713
IJPRBS
13. Pal D K and Nayak A K: Nanotechnology For Targeted Delivery In Cancer Therapeutics, Int J Pharm Sci Rev Res. 2010; 1: 1.
14. Li C: Poly (L-glutamic acid)-anticancer drug conjugates, Adv Drug Deliv Rev. 2002; 54: 695.
15. Praetorius N P and Mandal T K: Engineered Nanoparticles in Cancer Therapy, Recent Pat Drug Deliv Formul. 2007; 1: 37.
16. Medina C, Santos-Martinez M J, Radomski A, Corrigan O I & Radomski M W, Nanoparticles: pharmacological and toxicological significance, Bri J Pharm, 150 (2007) 552.
17. Ravi Kumar M N V: Nano and microparticles as controlled drug delivery devices, J Pharm Pharmaceut Sci. 2000; 3: 234.
18. Jain P, Mishra A, Yadav S K, Patil U K and Baghel U S: Formulation Development and Characterization of Solid Lipid Nanoparticles Containing Nimesulide, Int J Drug Deliv Tech. 2009; 1: 24.

Thank you for copying data from http://www.arastirmax.com